BIOMARIN PHARMACEUTICAL INC - NOTE 1.250% 5/1

Q2 2021 13F Holders as of 30 Jun 2021

Type / Class: Debt / NOTE 1.250% 5/1
Number of holders: 28
Total 13F principal, excl. options: 243,769,000
Principal change: +243,769,000
Total reported value, excl. options: $245,269,238
Value change: +$245,269,238
Number of buys: 28
Price: $1

Significant Holders of BIOMARIN PHARMACEUTICAL INC - NOTE 1.250% 5/1 as of Q2 2021

28 filings reported holding 09061GAK7 - BIOMARIN PHARMACEUTICAL INC - NOTE 1.250% 5/1 as of Q2 2021.
BIOMARIN PHARMACEUTICAL INC - NOTE 1.250% 5/1 has 28 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of $243,769,000 of principal .
Largest 10 bondholders include ADVENT CAPITAL MANAGEMENT /DE/ ($70,652,000 of principal), MACKAY SHIELDS LLC ($24,500,000 of principal), UBS ASSET MANAGEMENT AMERICAS INC ($23,000,000 of principal), CNH PARTNERS LLC ($21,650,000 of principal), DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main ($15,700,000 of principal), STATE STREET CORP ($15,316,000 of principal), SHENKMAN CAPITAL MANAGEMENT INC ($14,821,000 of principal), LAZARD ASSET MANAGEMENT LLC ($14,195,000 of principal), DEUTSCHE BANK AG\ ($8,813,000 of principal), and NEW YORK STATE COMMON RETIREMENT FUND ($7,593,000 of principal).
This table shows the top 28 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.

Investor	Option	Weight %	Change %	Value $	* Price $	Principal	Share Change	Activity	Report Period

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.